Phase 2
N=205
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
Diabetes Mellitus, Type 2
Bottom Line
View on ClinicalTrials.gov: NCT03951805 ↗Enrolled (actual)
205
Serious AEs
2.9%
Results posted
Jan 2021
Primary outcome: Primary: Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring) — 76.65; 82.97; 80.89; 75.89 Percentage of time — p=0.7675
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Insulin icodec (Drug); Insulin Glargine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Novo Nordisk A/S
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring) |
76.65; 82.97; 80.89; 75.89 | 0.7675 |
| SECONDARY Change in HbA1c (Glycated Haemoglobin) |
-1.00; -1.22; -1.38; -1.02 | — |
| SECONDARY Change in Fasting Plasma Glucose (FPG) |
-2.23; -2.42; -3.01; -2.34 | — |
| SECONDARY Change in Body Weight |
0.87; 1.11; 1.25; 0.63 | — |
| SECONDARY Weekly Insulin Dose |
142.47; 176.38; 208.90; 145.56 | — |
| SECONDARY Number of Treatment Emergent Adverse Events (TEAEs) |
44; 67; 58; 45 | — |
| SECONDARY Number of Severe Hypoglycaemic Episodes (Level 3) |
0; 0; 0; 0 | — |
| SECONDARY Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3) |
1; 2; 8; 0 | — |
| SECONDARY Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter) |
14; 20; 110; 10 | — |
Summary
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared. This is done to find the best way to change the dose of insulin 287. Participants will either get insulin 287 that they will have to inject once a week or insulin glargine that participants will have to inject once a day. Which treatment participants get is decided by chance. The study will last for about 5 months (23 weeks). Participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the study doctor will ask participants to:
* measure blood sugar every day with a blood sugar meter using a finger prick.
* write down different information in a diary daily and return this to the study doctor.
* wear a medical device (sensor) that measure blood sugar all the time for 18 weeks (about 4 months) during the study.
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.
Eligibility Criteria
Inclusion Criteria
- Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent
- Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening
- HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory
- Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):
- Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical records)
- Free or fixed combination therapy: Metformin as outlined above plus/minus DPP4i with or without SGLT2i is allowed:
i) DPP4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose) ii) SGLT2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose )
- Insulin-naïve. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes
- Body mass index (BMI) below or equal to 40.0 kg/m^2
Data sourced from ClinicalTrials.gov (NCT03951805). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.